Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis

World Journal of Pediatrics

Volumn 12, Issue 3, 2016, Pages 283-290

  Đurić Filipović, Ivana ^a   Caminati, Marco ^b   Kostić, Gordana ^c   Filipović, Đorđe ^d   Živković, Zorica ^e  

^a Department of Physiology   (Serbia)

^b BORGO TRENTO HOSPITAL   (Italy)

^c Clinical Centre Kragujevac   (Serbia)

^d Institute for Emergency Medical Aid Belgrade   (Serbia)

^e Children's Hospital for Pulmonary Diseases and Tuberculosis   (Serbia)

Author keywords

allergic asthma; allergic rhinitis; allergic sensitization; immunotherapy

Indexed keywords

ADRENALIN; ALLERGEN; IMMUNOGLOBULIN E; PLACEBO; POLLEN ANTIGEN; STALLERGEN;

ABDOMINAL PAIN; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BETULACEAE; DERMATOPHAGOIDES; DRUG EFFICACY; DRUG SAFETY; GRASS; HUMAN; MOUTH DISEASE; NONHUMAN; PARIETARIA; PHLEUM PRATENSE; POLLEN ALLERGY; RESPIRATORY TRACT ALLERGY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION; ADOLESCENT; CHILD; DESENSITIZATION; FEMALE; IMMUNOLOGY; MALE; PRESCHOOL CHILD; PROCEDURES; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ALLERGENS; ASTHMA; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; MALE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84976548693     PISSN: 17088569     EISSN: 18670687     Source Type: Journal    
DOI: 10.1007/s12519-016-0022-1     Document Type: Article

References (84)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper J Allergy Clin Immunol 1998;102:558–622.
2. Black JH. The oral administration of pollen: clinical report. J Lab Clin Med 1928;13:709–713.
3. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006;61:151–165.
4. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338–1345.
5. Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008;121:512–518.
6. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252–3259.
7. UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319–325.
8. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408–415.
9. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005;136:134–141.
10. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebocontrolled study. Allergy 2000;55:842–849.
11. Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005;136:287–294.
12. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, et al. Immune responses in healthy and allergic Individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567–1575.
13. Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Ruckert B, et al. GATA3-driven Th2 responses inhibit TGFbeta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:e329.
14. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221–224
15. Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003;112:1171–1177.
16. Gabrielsson S, Soderlund A, Paulie S, van der Pouw Kraan TC, Troye-Blomberg M, Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4 and IL-13-producing cells during pollen season. Allergy 2001;56:293–300.
17. Faith A, Richards DF, Verhoef A, Lamb JR, Lee TH, Hawrylowicz CM. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: relevance to immunotherapy. Clin Exp Allergy 2003;33:1209–1215.
18. Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47–53.
19. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14:216–221.
20. Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MAet al. Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol 2005;37:147–151.
21. Suárez-Fueyo A, Ramos T, Galán A, Jimeno L, Wurtzen PA, Marin A, et al. Grass tablet sublingual immunotherapy down regulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol 2014;133:130–138.
22. Hawrylowicz CM, O’Garra A. Potential role of interleukin-10 secreting regulatory T cells in allergy and asthma. Nature Rev Immunol 2005;5:271–283.
23. Taylor A, Verhagen J, Akdis CA, Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 2004;135:73–82.
24. Yazdanbakhsh M, Kremsner PG, Van Ree R. Allergy, parasites and the hygiene hypothesis. Science 2002;296:490–494.
25. Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4(1) CD25(1)T cells: multiple pathways on the road. J Cell Physiol 2007;211:590–597.
26. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231–234.
27. Gambineri E, Torgerson T, Ochs H. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of Foxp3, a critical regulator of T cell homeostasis. Curr Opin Rhumatol 2003;15:430–435.
28. Gentile D, Schreiber R, Howe-Adams J, Trecki J, Patel A, Angelini B, et al. Diminished dendritic cell interleukin 10 production in atopic children. Ann Allergy Asthma Immunol 2004;92:538–544.
29. Ling EM. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608–615.
30. Akdis C, Joss A, Akdis M, Blaser K. Mechanisms of IL10 induced T cell inactivation in allergic inflammation and normal response to allergens. Int Arch Allergy Immunol 2001;124:180–182.
31. Akdis M, Akdis C. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014;133:621–631.
32. Tari G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A doubleblind study. Allergol Immunopathol (Madr) 1990;18:277–284.
33. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997;8:21–27.
34. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, André C, et al. Double blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662–672.
35. La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425–432.
36. Caffarelli C, Sensi LG, Marcucci F, Cavagni C. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial. Allergy 2000;55:1142–1147.
37. Yuksel H, Tanac R, Gousseinov A, Demir E. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy. J Investig Allergol Clin Immunol 1999;9:305–313.
38. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49–55.
39. Pajno GB, Vita D, Parmiani S, Caminiti L, La Grutta S, Barberio G. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin Exp Allergy 2003;33:1641–1647.
40. Wuthrich B, Bucher Ch, Jorg W, Bircher A, Eng P, Schneider Y, et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Investig Allergol Clin Immunol 2003;13:145–148.
41. Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Klimek L, et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004;59:498–504.
42. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebocontrolled study in Taiwan. Respir Med 2006;100:1374–1383.
43. Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:1177–1183.
44. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust miteinduced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18:47–57.
45. Roder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007;119:892–898.
46. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, De Beaumont O. Efficacy and safety of 5 grass pollen subllingualimmunotherapy in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160–166.
47. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, et al. Safety anefficacy in children of an SQstandardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167–173.
48. Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp Allergy 2009;39:401–408.
49. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy Allergy 2005;60:952–956.
50. Larenas-Linnemann D, Blaiss M, Van Bever HP, Compalati E, Baena-Cagnani CE Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol 2013;110:402–415.
51. Hedlin G, van HM. The role of immuntherapy in the managment of childhood asthma. Ther Adv Respir Dis 2012;127:30–38.
52. Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011;127:57–63.
53. Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18:508–515.
54. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen specific immunotherapy in childrem with asthma: a randomized controled trial. J Allergy Clin Immunol 2010;126:942–956.
55. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjuntivits and asthma. JAMA 2013;309:1278–1288.
56. Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol 2012;23:401.
57. Yoselin A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157:288–298.
58. Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Respir Med 2013;107:1322–1329.
59. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64–71, 71. e1-4.
60. Rodriguez-Perez N, Ambriz-Moreno AJ, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol 2008;101:304–310.
61. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006;61:1236–1237.
62. Blazowski L. Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008;63:374.
63. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immuno-therapy with grass pollen tablet. Allergy 2009;64:963–964.
64. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Postmarketing surveillance study on the safety of sublingual immunotherapy in children. Allergy 1999;54:1110–1113.
65. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing survey. Allergol Immunopathol 2004;32:76–81.
66. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy 2005;60:133.
67. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005;35:560–564.
68. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety of SLIT in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005;95:254–258.
69. Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, Canonica GW, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 2008;63:1637–1639.
70. De Castro G, Zicari AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, et al. Efficacy of sublilngual immunotherapy on allergic asthma in children’s real life. Eur Rev Med Pharmacol Sci 2013;17:2225–2231.
71. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? Expert Rev Clin Immunol 2013;9:937–947.
72. Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302–311.
73. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy 2011;41:1247–1255.
74. Medical Dictionary for Regulatory Activities (MedDRA). Maintenance support services and organization. http://www.meddra.com (Accessed October 1, 2014).
75. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:544–548.
76. Pajno GB, Caminiti L, Crisafulli G, Barberi S, Landi M, Aversa T, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 2012;23:688–689.
77. Senna G, Caminati M, Canonica GW. Safety and tolerability of sublingual immunotherapy in clinical trials and real life. Curr Opin Allergy Clin Immunol 2013;13:656–662.
78. Passalacqua G, Baena-Cagnani CE, Bousquet J, Canonica GW, Casale TB, Cox L, et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93–98.
79. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trias in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77–83.
80. Ciprandi G, Cadario G, Valle C, Ridolo E, Verini M, Di Gioacchino M, et al. Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol 2010;20:274–279.
81. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual swallow immunotherapy (SLIT) in patients with asthma due to house dust mites; a double blind placebo controlled study. Allergy 1999;54:249–260.
82. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45–53.
83. Kahlert H, Grage-Griebenow E, Stüwe HT, Cromwell O, Fiebig H. T cell reactivity with allergoids: influence of the type of APC. J Immunol 2000;165:1807–1815.
84. Ulrich JT1, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995;6:495–524.